Comprehensive and categorized actionable data generated via artificial intelligence and machine learning methods and curated by Life Science Experts.

Catailyst has combined automation and artificial intelligence to understand scientific, clinical and business announcements from various public information sources, such as press releases, SEC filings, trial registrations to create actionable and searchable data points. Catailyst has recently launched a database and data analytics platform to provide access to such data. The company has also developed several real-time alerts.

Integrated Platform with Reliable Data: Designed to Help Answer Critical Business Questions

The company aims to provide this data to its customers from a cloud based platform with SAAS (software as a service) subscription business model. The company brings a comprehensive solution for Biotech and Pharma business development teams, clinical development team, investment bankers, investors, and life science consultants to track drug development, monitor competition, follow market trends and inform about recent developments of drug candidates and approved drugs.


The Problem: Expensive and time consuming to find accurate data within life science industry

The life science industry is overwhelmed with data flow and executives, clinicians, researchers, investors, consultants, bankers are missing critical information. Companies may plan to spend money due to multiple subscriptions or a company individual may run many internet searches to assemble information. Moreover, there is not a single source for data and these databases are not integrated.

  • Poor Integration: Multiple Subscriptions
  • Labor Intensive: Manual Data Verification/Curation
  • High Subscription Cost

Additionally, development of a new drug takes a long time and it requires significant investments mainly due to many regulatory requirements defined as safety and efficacy requirements for the sought drug candidates for a particular disease. In addition, drug discovery always has a low overall success rate due to late failure in establishing benefits for patients compared to risk of taking a brand new medicine. Thus, every decision during the drug discovery and development, such as a go no-go decision, decision related to project prioritization, new strategic initiative, investment, and/or acquisition, relies on accurate and up to date information. Currently, access to such information is expensive via multiple database subscriptions. Alternatively, companies spend a lot of time searching for such information via a series of google searches.

To this end, small and medium size businesses are most challenged.


The Solution: Catailyst, Disrupting The Drug Discovery And Development With Data Science: AI, ML, NLP & Predictive Analytics

Catailyst has developed many proprietary methods of artificial intelligence involving machine learning and natural language processing methods to read and analyze different forms of texts announced daily such as press releases, SEC filings and trial registrations. Catailyst was in stealth for the last three years and during this time the company has developed several methods of artificial intelligence. A patent related to such invention was filed to USPTO in 2020 and the company filed PCT applications in certain countries from EU, Canada and India. No patents have been granted.

Catailyst has added business process automation to its artificial intelligence and enabled methods of identifying, extracting and categorizing relevant data points without human intervention. By implementing such a process, the Company processes 500+ press releases, 100+ clinical trials related information, and hundreds of SEC filings everyday.

Catailyst Technology: Automation, Proprietary Data Science (ML & NLP); Complex Methods of Know-How

In addition, by analyzing historical press releases, sec filings, and scientific abstracts the company has generated millions of data points. Certain methods involve extracting a relevant sentence from 200 page SEC filing documents such as 10Ks which presents a large amount of unstructured data. Our patent pending methods remove boring human repetitive work from the system.

It’s Easy-To-Use And Ready To Export:

  • Data At Your Fingertips within an intuitive platform with appropriate visualization
  • Pipeline by Indication
  • Conference abstracts and MOA
  • Competitive Intelligence and Market Landscape by development stage 
  • Future timeline for developments
  • Historic Data on abandoned projects and failed targets
  • Deal Terms and access to hard-to-find deal information available in few clicks

business model

Catailyst is currently offering two products. SAAS monthly subscriptions to the database and daily/weekly customizable alerts in a B2B business model.

Catailyst current and future customers are generally categorized in three major categories: the first set of customers from the Biotech and Pharma industry, a possible second set of customers are consultants and the third as investment bankers as they use information to help formulate company strategy or help the company with a transaction such as financing or acquisition.

Creating Value for Customers: Designed to Save Time and Money


Catailyst addressable markets intersect Life Science Analytics and Artificial Intelligence in Life Sciences. Both are rapidly growing markets.

success to date

  • 2019Q4 Partnership with Xelpmoc (Publicly Traded Indian company, listed at Bombay Stock Exchange)
  • 2020Q2 AWS Activate award, $25,000 USD grant
  • 2020Q2 First Advisor came on board
  • 2020Q2 US provisional patent application - Morgan Lewis
  • 2020Q3 Multiple Newswire partnerships: Globenewswire; Businesswire; Accesswire; PRNewswire
  • 2020-2023 Employed 13 paid short-term employees, employed during Covid-days
  • 2020-2023 Non-dilutive Mass Life Science Corporation Intern Challenge Program Funding
  • 2021Q2 Major data science technology breakthrough
  • 2021Q2 US patent conversion
  • 2022Q1 Beta Product Launch
  • 2022Q1 First Paid Customer in 2022
  • 2022Q4 PCT - International patent applications


Jit Basak
President, CEO
Jit Basak is the President and CEO of Catailyst Inc. Previously, he was a Transaction Lead of Corporate Development at Shire/Takeda; Inotek Pharmaceutical following Investment Banking Advisory roles. He was a FINRA-registered investment banker and has led transactional work with increasing responsibilities at Ferghana Partners and Capstone-Headwaters. Earlier in his career, Jit spent nine years as a medicinal chemist in multiple therapeutic areas at both midsize biotech and large pharmaceutical companies: Chemocentryx, Inc. and Pfizer, Inc. After completing his post-doctoral research at University of Chicago, he received his MBA from the University of Connecticut School of Business in finance and international business. Jit holds a PhD degree from University Illinois at Chicago in synthetic organic chemistry and master’s degree in chemistry from Indian Institute of Technology Kanpur, India.
Sandipan Chattopadhyay
Chief Technology Officer
Sandipan Chattopadhyay, aged 49 years, is the Managing Director and Chief Executive Officer of Xelpmoc. He holds a degree of Bachelor of Statistics (Honors) from the Indian Statistical Institute, Calcutta. He also holds a Post Graduate Diploma in Computer Aided Management from the Indian Institute of Management, Kolkata. He is primarily responsible for the performance and supervision of technical, administrative and day-to-day operations of , including but not limited to developing strategic plans, promotion of revenue, profitability and growth of Xelpmoc. He has more than 24 years of experience in the field of technology. Prior to joining Xelpmoc, he has served as the Chief Technical Officer at Just Dial Limited. He has been a Director on Xelpmoc Board since incorporation.
Naushad Vali 
Senior Technical Architect
Naushad is a highly skilled and experienced technology professional who embodies the traits of an enterprising and analytical mindset. With 18+ years of experience in the industry, he has built a comprehensive understanding of solution and system architecture, enabling them to deliver effective technology solutions. His implementation approach and deep functional knowledge make him a valuable asset in any technology project. Furthermore, his self-driven motivation and diligence ensure that he consistently produces high-quality results. He is poised to bring his unique blend of technical expertise and drive to any organization they work with. He has completed a Master's level program in Computer Applications. He also had work experience at some major Indian companies like Goibibo, Reliance BIG MAPS, and Justdial. Presently, Naushad is a Senior Tech Advisor at Xelpmoc. In almost all his previous experiences, he has started with companies at the time of inception and moved out once companies got success and went to almost an autopilot mode.


Use of Proceeds

If the offering's maximum amount of $1,235,000 is raised:

UseValue% of Proceeds
Salaries - Management$200,00016.2%
Advertising and Marketing$250,00020.2%
Legal and Professional Sevices$30,0002.4%
Research and Development$108,0008.7%
Salaries - Marketing$100,0008.1%
Salaries - Sales$180,00014.6%
Intermediary fees$60,5154.9%


This is an offering of Class A Common Stock, under registration exemption 4(a)(6), in Catailyst Inc. . This offering must raise at least $10,000 by October 16, 2023 at 10:59pm ET. If this offering doesn’t reach its target, then your money will be refunded. Catailyst may issue additional securities to raise up to $1,235,000, the offering’s maximum.

If the offering is successful at raising the maximum amount, then the company’s implied valuation after the offering (sometimes called its post-money valuation) will be:

$10 per share
$11,235,000implied valuation


These financial statements have been reviewed by an independent Certified Public Accountant.

SEC Filings

The Offering Statement is a formal description of the company and this transaction. It’s filed with the SEC to comply with the requirements of exemption 4(a)(6) of the Securities Act of 1933.

We’re also required to share links to each of the SEC filings related to this offering with investors.

Understand the Risks

Be sure to understand the risks of this type of investment. No regulatory body (not the SEC, not any state regulator) has passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials or information posted herein. That’s typical for Regulation CF offerings like this one.

Neither Netcapital nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.

The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

More Info


  • Sep 26, 2023
  • Sep 14, 2023
    Hope your summer went well. Two quick...

    Hope your summer went well. Two quick announcements.

    New Feature on the Platform: Catailyst team has been working adding certain features that were requested by the early adopters of the platform.

    MassBio Member Spotlights: Catailyst has been selected for MassBio member spotlights in October Newsletter for its efforts in advancing the life sciences industry and supporting the patients we serve. Stay tuned!!

    Don’t hesitate to reach out to us with your questions.


    Jit Basak, PhD MBA CEO at Catailyst

    More information here
  • Sep 1, 2023
  • Jul 6, 2023
  • Jun 16, 2023
    We super excited to inform you that Catailyst...

    We super excited to inform you that Catailyst is advancing to the semi-finalist round of Pepperdine University’s Most Fundable Companies competition.

    Based on Catailyst’s Qualifier Survey responses and Pepperdine Graziadio Business School research, Catailyst is now one of a select group of fewer than 100 semi-finalists chosen from over 3,000 participants nationwide.

    More exciting news to follow soon!!

    More information here
  • Jun 15, 2023
    Catailyst recently presented a poster at Orphan...

    Catailyst recently presented a poster at Orphan Drug Congress US. You could find the poster here. Accelerating Orphan Drug BD and R&D with Clinical, Scientific, and Transaction Data: Empowering Industry Professionals with Evidential Data and Extractive Artificial Intelligence

    Presented at World Orphan Drug Congress| May 23 - May 25, 2023 | All Rights Reserved

    Cheers, Jit

    world orphan drug conference 2023.pdf
  • Jun 14, 2023
    Hi Everyone, I hope you are able to attend our...

    Hi Everyone, I hope you are able to attend our Live Q&A tomorrow.

    Netcapital Live Q&A with Catailyst Date & Time Jun 15, 2023 03:00 PM Eastern Time (US and Canada) Webinar ID 824 2188 5043 Description Tune in for a live discussion with Catailyst, currently raising on Netcapital. We will start with some prepared questions, then allow potential investors to ask questions of the founders.

    More info:

    This event is run by the team at Netcapital Systems, LLC.

    Register Here
  • May 9, 2023
    In addition to recent partnership with Launchit...

    In addition to recent partnership with Launchit Venture to streamline the sales and marketing process, facilitate product development, and expand global product sales and customer acquisition. (

    Catailyst has added several new members to its team. We are super excited to welcome many great talents.

    We are welcoming following team members:

    1. Director of Content and Communications
    2. Life Science Data Analyst Trainee from Brandeis MS of Data Analytics (15 weeks, MLSC co-sponsored)
    3. Data Science and AI Innovation Trainee Biotech and Pharma from Northeastern University (25 weeks, MLSC co-sponsored)
    4. Sales and Marketing Trainee from MassBay Community College (24 weeks, MLSC co-sponsored)

    We are currently interviewing for two additional open positions!

  • May 9, 2023
    Catailyst is presenting a poster at World...

    Catailyst is presenting a poster at World Orphan Drug Congress USA 2023 May 23-25, 2023 Gaylord National Resort & Convention Center Washington, D.C.

    The World’s Most Important Orphan Drug and Rare Disease Event

    Read more
  • May 9, 2023
    Catailyst is looking forward to attend AWS Life...

    Catailyst is looking forward to attend AWS Life Sciences Executive Symposium!! Come join us.

    AWS Life Sciences Executive Symposium May 15, 2023 Hyatt Regency Boston / Cambridge, 575 Memorial Drive, Cambridge, MA 02139

    Unlocking data, analytics, and machine learning to accelerate innovation.

    About the event Life science organizations are at a turning point in how they use data science and machine learning (ML) to accelerate the research and development of life saving medicines. But, unlocking the true value of data and harnessing the power of ML to accelerate innovations requires executive leadership engagement and an end-to-end data strategy.

    The event will feature keynotes, lightning talks, product demos, and panel discussions across two parallel tracks:

    Track 1: Accelerating pharmaceutical drug discovery with ML Track 2: Unlocking access to and insights from data

    Read more
  • May 9, 2023
    Meet us at Bio-IT next week. Catailyst will be...

    Meet us at Bio-IT next week. Catailyst will be presenting a poster at Bio-IT World congress

    P09: Expediting Business, Scientific and Clinical Decisions with Evidential Data in a Few Clicks: Introducing Catailyst’s Extractive Artificial Intelligence for the Drug Development, Presented by Jit B., Catailyst

    The Bio-IT World Conference & Expo is the world’s premier event showcasing the technologies and analytic approaches that solve problems, accelerate science, and drive the future of precision medicine. For over 20 years, the Event has united a community of leading life sciences, pharmaceutical, clinical, healthcare, informatics, and technology experts in the fields of biomedical research, drug discovery & development, and healthcare from around the world. During May 16-18, 2023, the Bio-IT World Conference & Expo will return to the Hynes Convention Center in Boston.

    Read more
  • May 9, 2023
  • May 3, 2023
    Catailyst Forms Strategic Partnership with...

    Catailyst Forms Strategic Partnership with Launchit Ventures to Accelerate Sales, Marketing, and Product Development to Better Serve Pharmas, Biotech & Investors. This collaboration aims to streamline the sales and marketing process, facilitate product development, and expand global product sales and customer acquisition.

    About Launchit Ventures:

    Launchit Ventures is an Ontario, Canada based venture studio that combines funding, entrepreneurship, and business acumen with a shared business services model. By assembling the right team for each venture and nurturing new ideas, the studio offers a more predictable path to success. Launchit Ventures’ approach reduces costs and significantly increases the chances of success for the companies it supports.

    Read more
  • Apr 29, 2023
    Hi Everyone, Netcapital Demo Day presentation...

    Hi Everyone, Netcapital Demo Day presentation is available here for your reference. I hope you had a chance to learn more about Catailyst. Now, you are ready to join us. Ask us more questions, we will be happy to answer. Key differentiator for us that we have developed proprietary extractive artificial intelligence and with our unique data we plan to explore regenerative artificial experience. We started 4 years ago and we were in stealth developing these methods. Now, that everyone is waking up to AI, we are already have many developed methods and ready to leap to the next stage. We have some exciting news to share. You should expect to hear from us early next week. Regards, Jit

  • Apr 26, 2023
    Netcapital is hosting a Virtual Demo Day on...

    Netcapital is hosting a Virtual Demo Day on Wednesday, April 26, 2023 at 4pm ET Catailyst will be live at Netcapital’s April Demo Day. We are looking forward to seeing you there. Date & Time: Apr 26, 2023 04:00 PM Eastern Time (US and Canada) Webinar ID 824 3928 9169

    Thanks, Jit

  • Apr 20, 2023
    Hi Everyone, Thank you all for your continued...

    Hi Everyone, Thank you all for your continued interest in Catailyst. We have two quick updates for you.

    1) We posted our responses @ Netcapital’s Catailyst Discussion Board. You could easily access the page with the link below

    Don’t hesitate to ask us more questions. We will try to respond as soon as possible.

    2) Catailyst will be live during Netcapital’s Demo Day at 4 pm on Wednesday, April 26. I hope you could attend.

    Demo Day link invite:

    Have a great day! Jit

    Register for Netcapital's Demo day here
  • Apr 12, 2023
    Catailyst team members are planning to attend...

    Catailyst team members are planning to attend several conferences and events during the next few months.

    The Massachusetts Life Sciences Center, the Massachusetts Biotechnology Council, and the Massachusetts Medical Device Industry Council recently announced the launch of the Massachusetts Life Sciences Week, April 24-28, to celebrate and recognize the global leadership of the life sciences industry here in Massachusetts.

    We are super excited to share that we will participate in the celebration by attending two major events: MassBio’s 2023 State of Possible Conference on Tuesday, April 25 and The Align Summit on Wednesday, April 26. State of Possible Conference: Giving attendees the opportunity to learn from experts, hear from speakers, participate in discussions, and expand their professional networks. Align Summit: Will bring together innovative startups from life science sectors with potential partners and offer a full day of content, networking, and partnering.

    Read more
  • Mar 10, 2023
  • Mar 9, 2023
    Primary offering of 123,500 shares at $10
  • Mar 9, 2023
  • Mar 9, 2023

Ask a Question

Proofread your comment before submitting: once it's posted, you can’t edit or delete it. For the fastest help with the web site, email instead of commenting.

Looking to raise capital?
We can help turn your friends, family and customers into investors.

Learn more

Interested in more investment opportunities?
Browse all offerings currently available.

See more